We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philip Morris (PM) Focused on RRPS, Inks Deal with Parallax
Read MoreHide Full Article
Philip Morris International Inc. (PM - Free Report) has inked a deal with Parallax, in an attempt to move ahead with its strategy of expanding in the smoke-free products space. Canada-based Parallax, owned by leading pioneers in pulmonary research and medicine, provides low risk alternatives of tobacco.
Both the companies will work towards reduction of harmful tobacco products by developing an effective nicotine-delivery system including e- cigarettes, pipe tobacco, cigars and hookah that leverages the most advanced technologies in pulmonary medicine. Prior to this, the company has invested more than $4.5 million since 2008 to develop, substantiate and build manufacturing capacity for a wide range of smoke-free products.
Phillip Morris has long been focused on strengthening its reduced risk products (RRPs) category owing to consumers’ rising health consciousness, along with government’s strict regulations on tobacco products.
Markedly, the U.S. Food and Drug Administration (FDA) made it mandatory for tobacco companies to use precautionary labels on cigarette packets to encourage customers quit smoking. Also, the FDA is bent on drastically reducing nicotine in cigarettes to minimally addictive levels. Apart from these, the FDA had earlier announced that tobacco makers must seek marketing authorization for any tobacco product introduced after Feb 15, 2007. In fact, these hurdles also remain threats to other tobacco players like Altria Group (MO - Free Report) , Vector Group and British American Tobacco (BTI - Free Report) ,
Serious health hazards due to cigarette smoking have pushed consumers toward low-risk, RRP’s. In this regard, Phillip Morris has been undertaking plant conversions and transforming them from cigarette to RRPs manufacturing facilities. This was witnessed in the company’s Papastratos factory in Greece, for the production of HEETS, a unit used with IQOS. IQOS, a smokeless cigarette, is counted as one of the leading RRPs in the industry.
Also, Phillip Morris’ revenues from RRPs doubled (on a constant-currency basis) to $1,127 million, largely driven by increased sales of IQOS devices in the first quarter of 2018. Notably, RRP revenues during the first quarter represented 16.3% of the company’s overall net revenues.
We believe these upsides can help this Zacks Rank #3 (Hold) company counter the challenges it is facing in the tobacco space and revive the stock that has plunged 30.5% as compared to the industry’s decline of 27.9%.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius. Click for details >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Philip Morris (PM) Focused on RRPS, Inks Deal with Parallax
Philip Morris International Inc. (PM - Free Report) has inked a deal with Parallax, in an attempt to move ahead with its strategy of expanding in the smoke-free products space. Canada-based Parallax, owned by leading pioneers in pulmonary research and medicine, provides low risk alternatives of tobacco.
Both the companies will work towards reduction of harmful tobacco products by developing an effective nicotine-delivery system including e- cigarettes, pipe tobacco, cigars and hookah that leverages the most advanced technologies in pulmonary medicine. Prior to this, the company has invested more than $4.5 million since 2008 to develop, substantiate and build manufacturing capacity for a wide range of smoke-free products.
Phillip Morris has long been focused on strengthening its reduced risk products (RRPs) category owing to consumers’ rising health consciousness, along with government’s strict regulations on tobacco products.
Markedly, the U.S. Food and Drug Administration (FDA) made it mandatory for tobacco companies to use precautionary labels on cigarette packets to encourage customers quit smoking. Also, the FDA is bent on drastically reducing nicotine in cigarettes to minimally addictive levels. Apart from these, the FDA had earlier announced that tobacco makers must seek marketing authorization for any tobacco product introduced after Feb 15, 2007. In fact, these hurdles also remain threats to other tobacco players like Altria Group (MO - Free Report) , Vector Group and British American Tobacco (BTI - Free Report) ,
Serious health hazards due to cigarette smoking have pushed consumers toward low-risk, RRP’s. In this regard, Phillip Morris has been undertaking plant conversions and transforming them from cigarette to RRPs manufacturing facilities. This was witnessed in the company’s Papastratos factory in Greece, for the production of HEETS, a unit used with IQOS. IQOS, a smokeless cigarette, is counted as one of the leading RRPs in the industry.
Also, Phillip Morris’ revenues from RRPs doubled (on a constant-currency basis) to $1,127 million, largely driven by increased sales of IQOS devices in the first quarter of 2018. Notably, RRP revenues during the first quarter represented 16.3% of the company’s overall net revenues.
We believe these upsides can help this Zacks Rank #3 (Hold) company counter the challenges it is facing in the tobacco space and revive the stock that has plunged 30.5% as compared to the industry’s decline of 27.9%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>